
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated significant financial growth, with sales increasing by 40% in the third quarter of 2025 compared to the same period in 2024, driven by strong performances from key products like Repatha and Tezspire. The company reported that 16 products achieved double-digit growth in the same quarter, indicating robust demand across its therapeutic portfolio. Furthermore, Amgen raised its fiscal year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, highlighting the firm's ongoing strength and commitment to innovation with increased investment in research and development projected to grow by over 20% in 2025.
Bears say
The analysis indicates that Amgen is projected to experience minimal total revenue growth of approximately 1% in 2026 compared to 2025, primarily due to significant anticipated sales declines of around 28% for Prolia and 39% for Xgeva. While there is potential in emerging products and the pipeline, specifically MariTide and olpasiran, there is insufficient visibility regarding their capacity to counterbalance the erosion from the base business. Additionally, the company is facing structural challenges related to the impending loss of exclusivity for key product franchises, which further contributes to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares